| 143.41 1.02 (0.72%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 170.18 |
1-year : | 198.78 |
| Resists | First : | 145.71 |
Second : | 170.18 |
| Pivot price | 139 |
|||
| Supports | First : | 139.61 |
Second : | 135.85 |
| MAs | MA(5) : | 140.29 |
MA(20) : | 139.49 |
| MA(100) : | 145.97 |
MA(250) : | 148.87 |
|
| MACD | MACD : | -0.9 |
Signal : | -1.7 |
| %K %D | K(14,3) : | 73.2 |
D(3) : | 52.9 |
| RSI | RSI(14): 58.9 |
|||
| 52-week | High : | 168.11 | Low : | 130.96 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABBV ] has closed Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 142.88 - 143.41 | 143.41 - 143.83 |
| Low: | 136.59 - 137.25 | 137.25 - 137.79 |
| Close: | 141.38 - 142.42 | 142.42 - 143.25 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sun, 03 Dec 2023
AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition (NYSE:ABBV) - Seeking Alpha
Fri, 01 Dec 2023
AbbVie: $10 Billion Cancer Deal To Boost Growth (NYSE:ABBV) - Seeking Alpha
Fri, 01 Dec 2023
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion - Yahoo Finance
Thu, 30 Nov 2023
AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and Dealmaker - TipRanks.com - TipRanks
Thu, 30 Nov 2023
AbbVie Stock (NYSE:ABBV): Bet on a Smart Drugmaker and ... - Yahoo Finance
Thu, 30 Nov 2023
Why Abbvie Stock Popped Today - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—General
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 71.4 (%) |
| Shares Short | 13,230 (K) |
| Shares Short P.Month | 12,310 (K) |
| EPS | 3.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.84 |
| Profit Margin | 11.8 % |
| Operating Margin | 17.7 % |
| Return on Assets (ttm) | 8.6 % |
| Return on Equity (ttm) | 46.3 % |
| Qtrly Rev. Growth | -6 % |
| Gross Profit (p.s.) | 23.46 |
| Sales Per Share | 31.15 |
| EBITDA (p.s.) | 15.81 |
| Qtrly Earnings Growth | -54.8 % |
| Operating Cash Flow | 25,510 (M) |
| Levered Free Cash Flow | 24,070 (M) |
| PE Ratio | 39.28 |
| PEG Ratio | -3 |
| Price to Book value | 20.93 |
| Price to Sales | 4.6 |
| Price to Cash Flow | 9.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|